Biological Study of Advanced Follicular Lymphoma Using Samples From FILFOLL12 Trial to Understand EZH2 Mutations and Other Biomarkers

What this Trial Is About

Researchers are investigating advanced follicular lymphoma FL by studying the role of EZH2 gene changes in patients treated with immunochemotherapy. This study is linked to the FILFOLL12 trial, which enrolled 807 patients and compared first-line treatments using chemoimmunotherapy combinations like R-CHOP or bendamustine-rituximab BR. The goal is to find biomarkers that can guide doctors in selecting the best chemotherapy approach for each patient. The study involves analyzing biological samples such as bone marrow, peripheral blood, and diagnostic tumor tissue. Tests include detecting EZH2 mutations using droplet digital PCR and examining gene expression patterns with RNA sequencing. Researchers will also explore other markers related to disease diversity, minimal residual disease, genetic factors, and microbiome profiles. These tests build on samples collected during the original FILFOLL12 trial. Participants have already been enrolled in the FILFOLL12 trial and provided biological samples. Researchers will measure outcomes like progression-free survival up to 43 months after treatment start, response rates within several months, and the relationship between gene mutations and expression patterns. The study is observational and focuses on laboratory analyses without additional treatments. It aims to provide practical biomarkers for clinical use and establish a network of laboratories for timely testing.

Multilayer Biological Characterization of Advanced Follicular Lymphoma: a Translational Study From FIL_FOLL12 Trial